RASi use was associated with fewer problems in the mobility and usual activities dimensions, whilst higher PTH (15.8–56.0 pmol/L) was associated with fewer issues in usual activities and anxiety and depression dimensions [compared with PTH low to normal (0–7.1 pmol/L)]. This evidence concerns the gene PTH and major depressive disorder.